scispace - formally typeset
T

Thanh-Dao Tran

Researcher at Ho Chi Minh City Medicine and Pharmacy University

Publications -  38
Citations -  531

Thanh-Dao Tran is an academic researcher from Ho Chi Minh City Medicine and Pharmacy University. The author has contributed to research in topics: Chalcone & Medicine. The author has an hindex of 8, co-authored 29 publications receiving 346 citations.

Papers
More filters
Journal ArticleDOI

Synthesis and Antibacterial Activity of Some Heterocyclic Chalcone Analogues Alone and in Combination with Antibiotics

TL;DR: Compounds f5, f6 and t5 are potential candidates for future drug discovery and development and had strong activities against both susceptible and resistant Staphylococcus aureus strains, but not activity against a vancomycin and methicillin resistant StAPHylococci strains isolated from a human sample.
Journal ArticleDOI

Inhibitory activity of prostaglandin E2 production by the synthetic 2′-hydroxychalcone analogues: Synthesis and SAR study

TL;DR: A series of 2'-hydroxychalcones has been synthesized and screened for their in vitro inhibitory activities of cyclooxygenase-2 catalyzed prostaglandin production from lipopolysaccharide-treated RAW 264.7 cells, and structure-activity relationship study suggested that inhibitory activity against prostaglandsin E(2) production was governed to a greater extent by the substituent on B ring of the chalcone.
Journal ArticleDOI

Computational predictive models for P-glycoprotein inhibition of in-house chalcone derivatives and drug-bank compounds.

TL;DR: Hit compounds for reversing MDR were discovered from the in-house and DrugBank databases through virtual screening using prediction models and molecular docking in an attempt to restore cancer cell sensitivity to cytotoxic drugs.
Journal ArticleDOI

Virtual Screening for Novel Staphylococcus Aureus NorA Efflux Pump Inhibitors From Natural Products

TL;DR: QSAR analysis, virtual screening and molecular docking were implemented in an effort to discover novel SA NorA efflux pump inhibitors to analyze the binding ability by docking studies on NorA homology model.